Thalassemia: Clinical Trials

64 trials for Thalassemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

33 completed, 9 active not recruiting, 8 terminated, 7 recruiting. 64 Phase 1, 29 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 164Completed 33, Active not recruiting 9, Terminated 8, Recruiting 7, Unknown 5, Enrolling by invitation 1, Withdrawn 1
Phase 229Completed 11, Active not recruiting 7, Recruiting 3, Terminated 3, Unknown 3, Enrolling by invitation 1, Withdrawn 1

Follow Thalassemia: new trials by email Literature Review of Thalassemia trials Research Report on Thalassemia

Trials (filtered) newest first · largest first

All 64 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
Total Body Irradiation, Alemtuzumab, Abatacept - Sickle Cell Disease, Beta-thalassemia
Phase 1 / Phase 2RecruitingNational Heart, Lung, and Blood Institute (NHLBI)902026-07-082026-10-13
Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease
Pociredir - Sickle Cell Disease
Phase 1TerminatedFulcrum Therapeutics132025-12-132026-06-18
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein, Sequencing Assay for Variant rs114518452 - Sickle Cell Disease, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Phase 1RecruitingDaniel Bauer102025-12-012026-02-03
A Study on the Effect of Etavopivat on Heart Rhythm in Healthy Participants
Etavopivat, Moxifloxacin, Placebo - Healthy Volunteers, Sickle Cell Disease
Phase 1CompletedNovo Nordisk A/S332025-06-092026-01-02
ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia
ALS20 - Beta-Thalassemia
Phase 1 / Phase 2Active not recruitingChildren's Hospital of Philadelphia122025-04-142026-10-29
A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants
Etavopivat, Digoxin, Pitavastatin - Healthy Volunteers Sickle Cell Disease, Thalassemia
Phase 1CompletedNovo Nordisk A/S372025-02-062026-09-29
A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia
9MW3011, 9MW3011 placebo - Beta-Thalassemia
Phase 1RecruitingMabwell (Shanghai) Bioscience Co., Ltd.402024-12-302025-01-14
A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese Participants
Etavopivat - Healthy Volunteers, Sickle Cell Disease
Phase 1CompletedNovo Nordisk A/S242024-08-262025-12-29
Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.
β-globin restored autologous hematopoietic stem cells - Β-thalassemia
Phase 1RecruitingShenzhen Hemogen82024-06-122024-10-23
A Research Study of the Effect of Food on Etavopivat in Healthy Participants
Etavopivat - Healthy Volunteers Sickle Cell Disease, Thalassemia
Phase 1CompletedNovo Nordisk A/S162024-05-282025-10-10
An Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia
Vebeglogene autotemcel - Beta-Thalassemia
Phase 1 / Phase 2Active not recruitingLantu Biopharma62024-05-112026-06-15
A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major
CS-101 injection - Beta-Thalassemia Major
Phase 1CompletedCorrectSequence Therapeutics Co., Ltd92024-04-182026-02-10
NAC Effect on Iron Overload and Blood Transfusion in β-thalassemia Major
n-acetylcystine - Thalassemia Major
Phase 1UnknownAssiut University1002024-03-232023-08-23
Safety & Efficacy of Thalidomide in Children With Transfusion Dependent Thalassemia
Thalidomide Capsules, Placebo - Transfusion-dependent Thalassemia
Phase 1CompletedBangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh602023-03-012024-04-09
Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia
BRL-101 - Beta-Thalassemia
Phase 1 / Phase 2Active not recruitingBioray Laboratories392022-11-022026-07-21
Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia
TBI, Hydroxyurea, briquilimab - Sickle Cell Anemia, Beta Thalassemia
Phase 1 / Phase 2Active not recruitingNational Heart, Lung, and Blood Institute (NHLBI)402022-05-122026-03-12
EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)
EDIT-301 - Transfusion Dependent Beta Thalassemia, Hemoglobinopathies
Phase 1 / Phase 2Active not recruitingEditas Medicine, Inc.92022-04-292025-04-02
Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia
Abatacept, Sirolimus - Thalassemia in Children
Phase 1 / Phase 2RecruitingThe Hospital for Sick Children202022-03-222023-12-19
A Safety and Efficacy Study Evaluating ET-01 in Subjects with Transfusion Dependent Β-Thalassaemia
ET-01 - Transfusion Dependent Beta-Thalassaemia
Phase 1TerminatedEdiGene (GuangZhou) Inc.82021-08-172025-03-30
The BENeFiTS Trial in Beta Thalassemia Intermedia
Benserazide Only Product - Beta Thalassemia Intermedia, Sickle Cell Disease
Phase 1 / Phase 2Enrolling by invitationPhoenicia BioScience362020-10-052025-08-15

Showing 20 of 64. Sign in to see all of them.

Narrower conditions

beta-Thalassemia (35)  ·  Anemia, Sickle Cell (31)  ·  Hemoglobinopathies (9)  ·  Anemia, Diamond-Blackfan (8)  ·  Anemia (6)  ·  Anemia, Aplastic (4)  ·  Fanconi Anemia (4)  ·  Granulomatous Disease, Chronic (4)  ·  Iron Overload (4)  ·  Mucopolysaccharidosis I (4)  ·  Genetic Diseases, Inborn (3)  ·  Hemoglobin SC Disease (3)  ·  Lymphohistiocytosis, Hemophagocytic (3)  ·  Myelodysplastic Syndromes (3)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (64)  ·  Hemic and Lymphatic Diseases (64)  ·  Anemia, Hemolytic (62)  ·  Anemia, Hemolytic, Congenital (62)  ·  Hematologic Diseases (62)  ·  Genetic Diseases, Inborn (61)  ·  Anemia (58)  ·  Hemoglobinopathies (55)  ·  Nutritional and Metabolic Diseases (11)  ·  Metabolic Diseases (10)  ·  Bone Marrow Diseases (9)  ·  Immune System Diseases (9)  ·  Anemia, Hypoplastic, Congenital (8)  ·  Red-Cell Aplasia, Pure (8)

Interventions

Alemtuzumab (7)  ·  Sirolimus (5)  ·  Hydroxyurea (4)  ·  Abatacept (3)  ·  fludarabine (3)  ·  AP 1903 reagent (2)  ·  Cyclophosphamide (2)  ·  Deferasirox (2)  ·  Deferoxamine (2)  ·  Hematopoietic Stem Cell Transplantation (2)  ·  Melphalan (2)  ·  Mycophenolic Acid (2)  ·  Tacrolimus (2)  ·  Thiotepa (2)  ·  2,2-dimethylbutyric acid (1)

Sponsors

National Heart, Lung, and Blood Institute (NHLBI) (6)  ·  Novo Nordisk A/S (4)  ·  Bellicum Pharmaceuticals (3)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3)  ·  Children's Hospital of Philadelphia (2)  ·  Gamida Cell ltd (2)  ·  Hangzhou Zede Pharma-Tech Co., Ltd. (2)  ·  Abdullah Kutlar (1)  ·  Assiut University (1)  ·  Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1)  ·  Beni-Suef University (1)  ·  Bioray Laboratories (1)  ·  Catherine Bollard (1)  ·  Celgene (1)  ·  Children's Hospital Los Angeles (1)

Countries

United States (39)  ·  China (10)  ·  Canada (5)  ·  Thailand (4)  ·  Italy (3)  ·  Australia (2)  ·  France (2)  ·  Lebanon (2)  ·  United Kingdom (2)  ·  Bangladesh (1)  ·  Egypt (1)  ·  Iran (1)  ·  Jamaica (1)  ·  Singapore (1)  ·  Turkey (Türkiye) (1)

Top investigators

John F Tisdale, M.D. (4)  ·  Abdullah Kutlar, MD (1)  ·  Alessandro Aiuti, MD, PhD (1)  ·  Allistair Abraham, MD (1)  ·  Angela E Rankine- Mullings, MD (1)  ·  Biljana Horn, MD (1)  ·  Chao Liu, PHD (1)  ·  Courtney D Fitzhugh, M.D. (1)  ·  Ellis Neufeld, MD (1)  ·  Erica Esrick, MD (1)  ·  Fabio Ciceri, MD (1)

Results publications

PMID 36240296, PMID 42133908, PMID 17536019, PMID 17620452, PMID 18439858, PMID 20007560, PMID 21742281, PMID 22875626, PMID 24296492, PMID 24916507, PMID 25058217, PMID 25222041, PMID 25938131, PMID 26348869, PMID 26589907, PMID 27862048, PMID 28249145, PMID 29455932, PMID 29669226, PMID 33283990, PMID 33560399, PMID 34175041, PMID 34795208, PMID 34917079, PMID 35075288, PMID 35745672, PMID 36058507, PMID 36637054, PMID 36690839, PMID 37975597, PMID 39722321, PMID 39891377, PMID 40010689, PMID 41871072, PMID 41931048, PMID 41984996, PMID 42233421

NIH funding

2014 (1), 2017 (1), R01DK055463 (1), R33HL147845 (1)